Edition:
India

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

5.32USD
12:55am IST
Change (% chg)

$-0.28 (-4.91%)
Prev Close
$5.60
Open
$5.59
Day's High
$5.64
Day's Low
$5.32
Volume
131,277
Avg. Vol
207,236
52-wk High
$9.11
52-wk Low
$4.82

Latest Key Developments (Source: Significant Developments)

Corbus Pharmaceuticals Reports Q1 2019 Results
Thursday, 9 May 2019 

May 9 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS 2019 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES.Q1 LOSS PER SHARE $0.43.Q1 EARNINGS PER SHARE ESTIMATE $-0.27 -- REFINITIV IBES DATA.QTRLY REVENUE FROM AWARDS $1.9 MILLION VERSUS $950,442.Q1 REVENUE VIEW $1.5 MILLION -- REFINITIV IBES DATA.  Full Article

Corbus Pharma Announces Change Of Primary Endpoint In Ongoing Phase 3 Study In Systemic Sclerosis
Thursday, 18 Apr 2019 

April 18 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS ANNOUNCES CHANGE OF PRIMARY ENDPOINT IN ONGOING RESOLVE-1 PHASE 3 STUDY IN SYSTEMIC SCLEROSIS IN U.S. TO ACR CRISS FROM MRSS FOLLOWING MEETING WITH FDA.CORBUS PHARMACEUTICALS HOLDINGS INC - PHASE 3 PRIMARY ENDPOINT WILL NOW BE ALIGNED WITH THAT OF PREVIOUS PHASE 2 STUDY.CORBUS PHARMACEUTICALS HOLDINGS INC - PHASE 3 PRIMARY ENDPOINT WILL NOW BE ALIGNED WITH THAT OF PREVIOUS PHASE 2 STUDY.CORBUS PHARMACEUTICALS HOLDINGS INC - CHANGE IN MRSS WILL BECOME SECONDARY ENDPOINT.CORBUS PHARMACEUTICALS HOLDINGS INC - NO CHANGES TO CONDUCT OR SIZE OF PHASE 3 STUDY.CORBUS PHARMACEUTICALS HOLDINGS INC - REMAINS ON TRACK TO COMPLETE RESOLVE-1 STUDY IN FIRST HALF OF 2020.  Full Article

Corbus Pharmaceuticals Holdings Q4 Loss Per Share $0.30
Tuesday, 12 Mar 2019 

Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES.Q4 LOSS PER SHARE $0.30.Q4 EARNINGS PER SHARE ESTIMATE $-0.26 -- REFINITIV IBES DATA.CONTINUED PROGRESS IN FOUR ONGOING CLINICAL STUDIES AS LENABASUM MOVES TOWARDS EXPECTED 2020 TOPLINE DATA READOUTS IN SYSTEMIC SCLEROSIS AND CYSTIC FIBROSIS STUDIES.SECOND CLINICAL CANDIDATE CRB-4001 EXPECTED TO COMMENCE CLINICAL STUDIES IN 2019.CORBUS PHARMACEUTICALS HOLDINGS - EXPECTS CURRENT CASH & CASH EQUIVALENTS TO FUND OPERATIONS INTO Q4 OF 2020, BASED ON CURRENT PLANNED EXPENDITURES.CORBUS PHARMACEUTICALS HOLDINGS - CO'S CASH AND CASH EQUIVALENTS BALANCE AT DECEMBER 31, 2018 WAS ABOUT $41.7 MILLION.  Full Article

Corbus Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Friday, 25 Jan 2019 

Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CORBUS PHARMACEUTICALS HOLDINGS - INTENDS TO USE NET PROCEEDS OF OFFERING TO FUND ITS CONTINUED DEVELOPMENT OF LENABASUM AND COMPOUNDS RECENTLY LICENSED FROM JENRIN.  Full Article

Corbus Pharmaceuticals Reports Q2 Loss Per Share $0.21
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS REPORTS 2018 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.21.Q2 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.RECEIVED A $6.25 MILLION PAYMENT FROM CYSTIC FIBROSIS FOUNDATION DURING Q2.ENDED QUARTER WITH ABOUT $64.7 MILLION OF CASH AND CASH EQUIVALENTS.  Full Article

Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍​
Saturday, 6 Jan 2018 

Jan 5 (Reuters) - Corbus Pharmaceuticals Holdings Inc ::CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING ‍​.  Full Article

Corbus Pharmaceuticals Q3 loss per share $0.14
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Corbus Pharmaceuticals Holdings Inc : :Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements.Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.Q3 loss per share $0.14.Corbus Pharmaceuticals Holdings Inc - ‍company expects current cash on hand to fund operations into Q4 of 2019,based on current planned expenditures​.Corbus Pharmaceuticals Holdings Inc - qtrly revenue $796,312 versus $742,558.  Full Article

Corbus Pharma reports improvement in skin conditions in a mid-stage study
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study.Corbus Pharmaceuticals Holdings Inc - ‍Company on track to commence phase 3 study Q4 2017​.Corbus Pharmaceuticals Holdings Inc - Were no severe or serious adverse events and no clinically significant laboratory abnormalities related to drug​.Corbus Pharmaceuticals - "‍Our focus now is to ensure successful execution of our phase 3 study, and we are on track to commence this before year end"​.  Full Article

Corbus Pharma prices underwritten public offering of common stock
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock.Says public offering of 4.65 million common shares priced at $7.00 per share.  Full Article

Corbus Pharmaceuticals Holdings announces proposed public offering of common stock
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals Holdings Inc announces proposed public offering of common stock.Corbus Pharmaceuticals Holdings Inc - ‍Corbus intends to use proceeds of proposed offering to fund its continued development of anabasum, among others​.  Full Article